NEWFlashcards for any set of questions, quick-reference tables for breast, lung and prostate, and a month of access for every colleague you refer. See what changed

CNS: Post-operative cavity SRS

Free question published 11 November 2026

Central nervous systemPost-operative cavity SRS

A 58-year-old man with a solitary 3.5 cm cerebellar metastasis from renal cell carcinoma undergoes complete surgical resection. His extracranial disease is controlled and KPS is 90. The resection cavity is now 3.2 cm. What is the most appropriate postoperative management?

  1. AObservation with surveillance MRI, deferring radiotherapy
  2. BWhole-brain radiotherapy to reduce local and distant intracranial recurrence
  3. CStereotactic radiosurgery to the resection cavity
  4. DRepeat surgery to widen the resection margins
  5. EWhole-brain radiotherapy plus a cavity boost

Why C is correct

NCCTG N107C/CEC.3 (Brown, Lancet Oncology 2017) randomised patients with a resected brain metastasis to cavity stereotactic radiosurgery versus whole-brain radiotherapy. Cognitive decline was less frequent with SRS than with WBRT and overall survival did not differ, so cavity SRS is a less toxic standard of care that preserves cognition. It is preferred over WBRT for this fit patient with a fully resected single metastasis and controlled systemic disease.

And why the others are not

  • AIncorrect: leaving the cavity untreated risks high local recurrence; adjuvant cavity SRS improves local control.
  • BIncorrect: WBRT caused more cognitive decline than cavity SRS without a survival advantage in N107C.
  • DIncorrect: the metastasis is already completely resected, so further surgery is not indicated.
  • EIncorrect: adding WBRT to a boost reintroduces the cognitive toxicity that cavity SRS is designed to avoid.

Source NCCTG N107C/CEC.3 — postoperative cavity stereotactic radiosurgery versus whole-brain radiotherapy — Brown PD, Ballman KV, Cerhan JH, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC.3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18(8):1049-1060.

More free central nervous system questions

Sitting in February? Follow the twenty-week plan.

2,500+ cited questions like this one are waiting in the vault.

See plans and pricing